Merck Q4 2024 Earnings Preview: Headwinds ahead, but familiar strengths to persist
Truist Securities expressed confidence in its latest note that Merck will be able to navigate the upcoming Gardasil headwinds carrying over from 2024, along with some major patent cliffs, but it will take time to reflect in growth.
Merck: Q4 Earnings Snapshot
On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one-time gains and costs, came to $1.72 per share. The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $1.69 per share.
Key Takeaways Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of ...
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
Reports Q4 revenue $15.6B, consensus $15.51B. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including ...
Shares of Merck (NYSE: MRK) were trading lower on Tuesday. The drop comes as the S&P 500 gained 0.5% and the Nasdaq Composite ...
Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...
MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...
Maersk on Thursday reported fourth-quarter profits above forecasts and said it expects earnings this year to trail last year's level amid considerable macroeconomic uncertainties which could impact ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback